1
Adler LP, Faulhaber PF, Schnur KC et al (1997) Axillary lymphnode metastases:
Screening with (F-18)2-deoxy-2fluoro-D-glucose (FDG) PET. Radiology 203:323-7
2
Avril N, Dose J, Jänicke F, Ziegler S et al (1996) Assessment of axillary lymphnode
involvement in breast cancer patients with positron emission tomography using
radiolabeled 2-(fluorine-18)-fluoro-2-deoxyglucose. J. Natl. Cancer Inst. 88:12041209
3
Avril N, Schelling M, Dose J, Weber WA, Schwaiger M (1999) Utility of PET in
breast cancer. Clin. Positron Imag. 2:261-271
4
Bombardieri E, Gianni L (2004) Breast Cancer: diagnostic and therapeutic options.
Springer, Eur.J. Nucl Med. 31:S1-S186
5
Bos R, van der Hoeven J, van der Wall E et al (2002) Biological correlates of 18 F
fluordeoxyglucose uptake in human breast cancer measured by positron emission
tomography. J Clin Oncol 20:379-387
6
Buck AK, Schirrmeister H, Mattfeld T, Reske SN (2004) Biological characterization
of breast cancer by means of PET. Eur J Nucl Med Mol Imaging Suppl 1 31:S80S87
7
Daidone MG, Paradiso A, Gion M et al (2004) Biomolecular features of clinical
relevance in breast cancer. Eur J Nucl Med Mol Imaging Suppl 1 31:Sr-S14
8
DiMaggio C (2004) State of the art of current modalities for the diagnosis of breast
lesions. Eur J Nucl Med Mol Imaging 31:S56-S69
9
DiMaggio C (2004) State of the art of current modalities for the diagnosis of breast
lesions. Eur J Nucl Med Mol Imaging 31:S56-S69
10
Dionne L, Friede J, Blais R (1983) Internal mammary lymphoscintigraphy in breast
carcinoma - a surgeons perspective. Sem. Nucl. Med. 1:35-41
11
Ege GN (1976) Internal mammary lymphoscintigraphy. Radiology 118:101-107
12
Eubank WB, Mankoff DA, Takasugi J et al (2001) 18 Fluorodeoxyglucose positron
emission tomography to detect mediastinal or internal mammary metastases in breast
cancer. J Clin Oncol 19:3516-23
13
Flanagan FL et al (1998) PET in breast cancer. Semin Nucl Med 28:290-302
14
Heywang SH (1986) Anwendung von Gd-DTPA bei der kernspintomographischen
Untersuchung der Mamma. Fortschr. Röntgenstr. 145:565-571
15
Heywang SH (1986) Anwendung von Gd-DTPA bei der kernspintomographischen
Untersuchung der Mamma. Fortschr. Röntgenstr. 145:565-571
16
Holinski-Feder E, Brandau O, Nestel-Krämling C et al (1998) Genetik des erblichen
Mammakarzinoms. Dtsch. Ärztebl. 95:A600-605
17
ICP Breast Cancer Task Force (1994) Positron Emission Tomography(Clinical
applications and economic implications of PET in the assessment of axillary
lymphnode involvement in breast cancer-A retrospective study-. Abstract from ICP
Meeting :
18
Katzenellenbogen JA, Carlson KE, Heiman DF, Goswami R (1980) Receptor
binding radiopharmaceuticals for imaging breast tumors: Estrogen receptor
interactions and selectivity of tissue uptake of halogenated estrogen analogs. J. Nucl.
Med. 21:550-558
19
Khalkhali I, Diggles LE, Taillefer R, Vandestreck PR et al (1999) Procedure
guidelines for breast scintigraphy. J. Nucl. Med. 40:1233-1235
20
Khalkhali I, Diggles LE, Taillefer R, Vandestreck PR et al (1999) Procedure
guidelines for breast scintigraphy. J. Nucl. Med. 40:1233-1235
21
Kinoshita T, Odagiri K, Andoh K et al (1999) Evaluation of small internal mammary
lymph node metastases in breast cancer by MRI. Radiat Med 17:189-193
22
Line BR, Mitra A, Nan A, Ghandehari H (2005) Targeting tumor angiogenesis:
Comparison of peptide and polymer-peptide conjugates. J Nucl Med 46:1552-1560
23
Mankoff DA, Muzi M, Krohn KA (2003) Quantitative positron emission
tomography imaging to measure tumor response to therapy; What is the best nethod
?. Molecular Imaging and Biology 5:281-285
24
McGuire AH, Dehdashti F, Siegel A et al (1991) Positron tomographic assessment
of 16 alpha-(18 F ) fluoro-17 Beta-estradiol uptake in metastatic breast carcinoma. J.
Nucl. Med. 32:1526-1531
25
Minn H, Soini I (1989) 18 F-fluorodeoxyglucose scintigraphy in diagnosis and
follow up of treatment in advanced breast cancer. Eur. J. Nucl. Med. 15:61-66
26
Miraldi F (1986) Potential of NMR and PET for determining tumor metabolism. Int.
J. Rad. Oncol. Biol. Phys. 12:1033-1039
27
Moon DH, Maddahi J, Silverman DHS et al (1998) Accuracy of whole body fluorine
18 FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl
Med :431-435
28
Paans AMJ, Vaalburg W, Woldring MG (1985) A comparison of the sensitivity of
PET and NMR for in vivo quantitative metabolic imaging. Eur. J. Nucl. Med. 11:7375
29
Rieker O, Grünwald F, Layer G et al (1994) Disseminated bone marrow metastases
from primary breast cancer: detection and follow-up by radioimmune bone marrow
scintigraphy. J Nucl Med
30
Rosenthal LJ (2001) Mechanisms of DNA Tumor Virus Transformation. Karger
Basel, :
31
Scheidhauer K, Scharl A, Schicha H (1998) Estrogen receptor scintigraphy. Q J
Nucl Med. 42:2326
32
Schillaci O, Buscombe JR (2004) Breast scintigraphy today:indications and
limitations. Eur J Nucl Med Mol Imaging Suppl 1 31:S35-S45
33
Szabo BK, Aspelin B, Kristoffersen Wiberg M, Tot T et al (2003) Invasive breast
cancer : correlation od dynamic MR features with prognostic factors. Eur Radiol
13:2425-2435
34
Torabi M, Aquino SL, Harisinghani M (2004) Current concepts in lymph node
imaging. J Nucl Med 45:1509-18
35
Wahl RL, Hutchins GD, Cody RL, Mudgett EE (1991) Primary and metastatic
breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose
analogue 2-(F-18)-fluoro-2-deoxy-D-glucose. Radiology 179:765-770
36
Wahl RL, Quint LE, Cieslak RD, Aisen AM, Koeppe RA, Meyer CR (1993)
''Anatometabolic'' tumor imaging: Fusion of FDG PET with CT or MRI to localize
foci of increased activity. J. Nucl. Med. 34:1190-1197
37
Yutani K, Tatsumi M, Shiba E, Kusuoka H, Nishimura T (1999) Comparison of dual
head coincidence gamma camera FDG imaging with FDG PET in detection of breast
cancer and axillary lymphnode metastasis. J. Nucl. Med. 40:1003-1008
Stichworte: Frau, Brust, Tumor, SPECT, F-18